Ascentage Pharma Group International (HKG:6855) narrowed its attributable loss in 2024 to 405.4 million yuan from 925.6 million yuan in the year-ago period, a Thursday filing with the Hong Kong bourse said.
Loss per share stood at 1.34 yuan, narrower than 3.28 yuan in 2023.
The drugmaker's revenue for the year increased by 342% to 980.7 million yuan from 222 million yuan a year prior.
The higher revenue was partly attributable to intellectual property income from Takeda Pharmaceuticals International and the strong sales growth of olverembatinib.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。